Financhill
Buy
51

LMAT Quote, Financials, Valuation and Earnings

Last price:
$81.42
Seasonality move :
10.14%
Day range:
$78.35 - $81.48
52-week range:
$71.42 - $109.58
Dividend yield:
0.89%
P/E ratio:
41.11x
P/S ratio:
8.22x
P/B ratio:
5.29x
Volume:
205.8K
Avg. volume:
193.8K
1-year change:
2.29%
Market cap:
$1.8B
Revenue:
$219.9M
EPS (TTM):
$1.98

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LMAT
LeMaitre Vascular
$60.7M $0.54 11.88% 8.76% $104.50
IART
Integra Lifesciences Holdings
$418.8M $0.58 -5.53% 241.78% $16.13
ISRG
Intuitive Surgical
$2.4B $1.96 16.8% 32.43% $575.78
MASI
Masimo
$369.6M $1.13 -25.72% 321.55% $182.07
PODD
Insulet
$643.9M $1.10 25.32% -63.95% $328.73
TFX
Teleflex
$790.6M $3.37 2.91% 98.97% $157.62
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LMAT
LeMaitre Vascular
$81.40 $104.50 $1.8B 41.11x $0.20 0.89% 8.22x
IART
Integra Lifesciences Holdings
$12.30 $16.13 $955.9M 70.14x $0.00 0% 0.58x
ISRG
Intuitive Surgical
$539.54 $575.78 $193.4B 79.11x $0.00 0% 22.47x
MASI
Masimo
$150.13 $182.07 $8.1B 116.80x $0.00 0% 4.13x
PODD
Insulet
$321.36 $328.73 $22.6B 57.80x $0.00 0% 10.81x
TFX
Teleflex
$120.78 $157.62 $5.3B 38.10x $0.34 1.13% 1.87x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LMAT
LeMaitre Vascular
32.58% 2.765 8.86% 13.65x
IART
Integra Lifesciences Holdings
54.74% 2.245 107.86% 0.57x
ISRG
Intuitive Surgical
-- 1.838 -- 3.81x
MASI
Masimo
40.75% 1.411 7.21% 0.87x
PODD
Insulet
56.03% 1.663 9.18% 3.24x
TFX
Teleflex
31.78% 0.827 30.89% 1.11x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LMAT
LeMaitre Vascular
$41.4M $12.6M 11.41% 13.74% 25.94% $7.7M
IART
Integra Lifesciences Holdings
$194.4M -$15.5M -0.86% -1.88% -2.93% -$40.2M
ISRG
Intuitive Surgical
$1.5B $578.1M 15.82% 15.82% 25.66% $465M
MASI
Masimo
$234M $80.7M -24.62% -39.91% 20.75% $27M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
TFX
Teleflex
$389.4M $130.3M 2.43% 3.41% 18.2% $43.1M

LeMaitre Vascular vs. Competitors

  • Which has Higher Returns LMAT or IART?

    Integra Lifesciences Holdings has a net margin of 18.39% compared to LeMaitre Vascular's net margin of -6.61%. LeMaitre Vascular's return on equity of 13.74% beat Integra Lifesciences Holdings's return on equity of -1.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.18% $0.48 $515.6M
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
  • What do Analysts Say About LMAT or IART?

    LeMaitre Vascular has a consensus price target of $104.50, signalling upside risk potential of 28.38%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 31.1%. Given that Integra Lifesciences Holdings has higher upside potential than LeMaitre Vascular, analysts believe Integra Lifesciences Holdings is more attractive than LeMaitre Vascular.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    IART
    Integra Lifesciences Holdings
    2 5 2
  • Is LMAT or IART More Risky?

    LeMaitre Vascular has a beta of 0.859, which suggesting that the stock is 14.076% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.765%.

  • Which is a Better Dividend Stock LMAT or IART?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.89%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or IART?

    LeMaitre Vascular quarterly revenues are $59.9M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. LeMaitre Vascular's net income of $11M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, LeMaitre Vascular's price-to-earnings ratio is 41.11x while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.22x versus 0.58x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.22x 41.11x $59.9M $11M
    IART
    Integra Lifesciences Holdings
    0.58x 70.14x $382.7M -$25.3M
  • Which has Higher Returns LMAT or ISRG?

    Intuitive Surgical has a net margin of 18.39% compared to LeMaitre Vascular's net margin of 30.99%. LeMaitre Vascular's return on equity of 13.74% beat Intuitive Surgical's return on equity of 15.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.18% $0.48 $515.6M
    ISRG
    Intuitive Surgical
    64.69% $1.92 $17.2B
  • What do Analysts Say About LMAT or ISRG?

    LeMaitre Vascular has a consensus price target of $104.50, signalling upside risk potential of 28.38%. On the other hand Intuitive Surgical has an analysts' consensus of $575.78 which suggests that it could grow by 6.72%. Given that LeMaitre Vascular has higher upside potential than Intuitive Surgical, analysts believe LeMaitre Vascular is more attractive than Intuitive Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    ISRG
    Intuitive Surgical
    14 10 1
  • Is LMAT or ISRG More Risky?

    LeMaitre Vascular has a beta of 0.859, which suggesting that the stock is 14.076% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

  • Which is a Better Dividend Stock LMAT or ISRG?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.89%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or ISRG?

    LeMaitre Vascular quarterly revenues are $59.9M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. LeMaitre Vascular's net income of $11M is lower than Intuitive Surgical's net income of $698.4M. Notably, LeMaitre Vascular's price-to-earnings ratio is 41.11x while Intuitive Surgical's PE ratio is 79.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.22x versus 22.47x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.22x 41.11x $59.9M $11M
    ISRG
    Intuitive Surgical
    22.47x 79.11x $2.3B $698.4M
  • Which has Higher Returns LMAT or MASI?

    Masimo has a net margin of 18.39% compared to LeMaitre Vascular's net margin of -45.89%. LeMaitre Vascular's return on equity of 13.74% beat Masimo's return on equity of -39.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.18% $0.48 $515.6M
    MASI
    Masimo
    62.9% -$3.17 $1.6B
  • What do Analysts Say About LMAT or MASI?

    LeMaitre Vascular has a consensus price target of $104.50, signalling upside risk potential of 28.38%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 21.28%. Given that LeMaitre Vascular has higher upside potential than Masimo, analysts believe LeMaitre Vascular is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    MASI
    Masimo
    4 3 0
  • Is LMAT or MASI More Risky?

    LeMaitre Vascular has a beta of 0.859, which suggesting that the stock is 14.076% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

  • Which is a Better Dividend Stock LMAT or MASI?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.89%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or MASI?

    LeMaitre Vascular quarterly revenues are $59.9M, which are smaller than Masimo quarterly revenues of $372M. LeMaitre Vascular's net income of $11M is higher than Masimo's net income of -$170.7M. Notably, LeMaitre Vascular's price-to-earnings ratio is 41.11x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.22x versus 4.13x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.22x 41.11x $59.9M $11M
    MASI
    Masimo
    4.13x 116.80x $372M -$170.7M
  • Which has Higher Returns LMAT or PODD?

    Insulet has a net margin of 18.39% compared to LeMaitre Vascular's net margin of 6.22%. LeMaitre Vascular's return on equity of 13.74% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.18% $0.48 $515.6M
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About LMAT or PODD?

    LeMaitre Vascular has a consensus price target of $104.50, signalling upside risk potential of 28.38%. On the other hand Insulet has an analysts' consensus of $328.73 which suggests that it could grow by 2.29%. Given that LeMaitre Vascular has higher upside potential than Insulet, analysts believe LeMaitre Vascular is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    PODD
    Insulet
    14 2 0
  • Is LMAT or PODD More Risky?

    LeMaitre Vascular has a beta of 0.859, which suggesting that the stock is 14.076% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

  • Which is a Better Dividend Stock LMAT or PODD?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.89%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or PODD?

    LeMaitre Vascular quarterly revenues are $59.9M, which are smaller than Insulet quarterly revenues of $569M. LeMaitre Vascular's net income of $11M is lower than Insulet's net income of $35.4M. Notably, LeMaitre Vascular's price-to-earnings ratio is 41.11x while Insulet's PE ratio is 57.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.22x versus 10.81x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.22x 41.11x $59.9M $11M
    PODD
    Insulet
    10.81x 57.80x $569M $35.4M
  • Which has Higher Returns LMAT or TFX?

    Teleflex has a net margin of 18.39% compared to LeMaitre Vascular's net margin of 13.56%. LeMaitre Vascular's return on equity of 13.74% beat Teleflex's return on equity of 3.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.18% $0.48 $515.6M
    TFX
    Teleflex
    55.58% $2.07 $6B
  • What do Analysts Say About LMAT or TFX?

    LeMaitre Vascular has a consensus price target of $104.50, signalling upside risk potential of 28.38%. On the other hand Teleflex has an analysts' consensus of $157.62 which suggests that it could grow by 30.5%. Given that Teleflex has higher upside potential than LeMaitre Vascular, analysts believe Teleflex is more attractive than LeMaitre Vascular.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    TFX
    Teleflex
    0 11 0
  • Is LMAT or TFX More Risky?

    LeMaitre Vascular has a beta of 0.859, which suggesting that the stock is 14.076% less volatile than S&P 500. In comparison Teleflex has a beta of 1.170, suggesting its more volatile than the S&P 500 by 17.034%.

  • Which is a Better Dividend Stock LMAT or TFX?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.89%. Teleflex offers a yield of 1.13% to investors and pays a quarterly dividend of $0.34 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or TFX?

    LeMaitre Vascular quarterly revenues are $59.9M, which are smaller than Teleflex quarterly revenues of $700.7M. LeMaitre Vascular's net income of $11M is lower than Teleflex's net income of $95M. Notably, LeMaitre Vascular's price-to-earnings ratio is 41.11x while Teleflex's PE ratio is 38.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.22x versus 1.87x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.22x 41.11x $59.9M $11M
    TFX
    Teleflex
    1.87x 38.10x $700.7M $95M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Gartner Stock Be in 5 Years?
Where Will Gartner Stock Be in 5 Years?

If you’ve ever wondered what it’s like to invest in…

Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?

Rambus has flown under the radar, but the numbers tell…

Celsius Stock Forecast: Will Earnings Spark Another Surge?
Celsius Stock Forecast: Will Earnings Spark Another Surge?

Energy drink seller Celsius Holdings, Inc. (NASDAQ:CELH) has reported somewhat…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock